Inuvair

Beclometasone dipropionate / Formoterol fumarate, the active ingredient in Inuvair, is an inhaled corticosteroid / long‑acting β2‑agonist combination presented as an inhalation aerosol (metered‑dose inhaler) for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Inuvair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Its company adheres to stringent quality standards and provides regulatory‑approved products to health‑care institutions across multiple continents. Its distribution network ensures reliable delivery and post‑market support for respiratory therapies.

Inuvair combines an inhaled corticosteroid with a long‑acting β2‑agonist, targeting the inflammatory and bronchoconstrictive components of chronic airway diseases. - Asthma: reduces airway inflammation and improves bronchodilation to help prevent symptoms and exacerbations. - Chronic obstructive pulmonary disease (COPD): provides long‑acting bronchodilation and anti‑inflammatory action to maintain lung function and reduce flare‑ups. - Exercise‑induced bronchoconstriction: may be incorporated into a maintenance regimen to control symptoms during physical activity.

Inhaled corticosteroid/long‑acting β2‑agonist combinations can be associated with a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness - Hoarseness or voice changes - Oral candidiasis (thrush) - Cough or wheezing after inhalation - Headache - Tremor

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with long‑term high‑dose use - Pneumonia, especially in COPD patients - Cardiac arrhythmias or tachycardia - Severe allergic reactions (anaphylaxis) - Hyperglycemia or worsening diabetes control

When prescribing Inuvair, clinicians should consider several safety measures to minimize risk. - Monitor for oral thrush: advise rinsing mouth after each inhalation. - Use with caution in patients with cardiovascular disease: assess heart rate and blood pressure. - Assess adrenal function during prolonged high‑dose therapy. - Avoid abrupt discontinuation: taper dose to prevent loss of control. - Use the lowest effective dose to achieve symptom control. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Inuvair may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: may reduce bronchodilator effect and precipitate bronchospasm. - Concurrent use of other inhaled corticosteroids: increases risk of systemic corticosteroid effects. - Monoamine oxidase inhibitors (MAOIs) combined with high‑dose β2‑agonists: risk of severe hypertension.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure to beclometasone. - Diuretics (especially loop diuretics): may potentiate hypokalemia from β2‑agonist activity. - Sympathomimetic drugs (e.g., pseudoephedrine): may enhance cardiovascular effects.